Atherosclerosis, 85 (1991) 265–267
Elsevier Scientific Publishers Ireland, Ltd.

Author Index (Vol. 85)

Alaupovic, P., see Koren, E. (38) 175
Alcolado, J.C., see Thorn, J.A. (85) 55
Armstrong, M.L. and Heistad, D.D.
Animal models of atherosclerosis (85) 15
Asada, Y., see Tanimura, N. (85) 161
Assadollahi, F., see Beaumont, J.-L. (85) 103

Babaev, V.R., Dergunov, A.D., Chenchik, A.A., Tararak, E.M., Yanushevskaya, E.V., Trakht, I.N., Sorg, C. and Smirnov, V.N.
Localization of apolipoprotein E in normal and atherosclerotic human aorta (85) 239
Barry, L.E. and Tan, M.H.
Changes in the composition of plasma lipoproteins in the chronic uremic rat (85) 139
Beaumont, J.-L. and Assadollahi, F.
Retinyl palmitate labeled intestinally derived lipoproteins accumulate in the circulation of WHHL rabbits (85) 103
Ben-Naim, M., see Harats, D. (85) 47
Betteridge, D.J., see Jay, R.H. (85) 249
Blömer, H., see Hauner, H. (85) 203
Bogaievsky, Y., see Simpson, H.S. (85) 193
Bond, M.G., see Shankar, R. (85) 37
Bonithon-Kopp, C., see Raison, J. (85) 185
Bonnefous, F., see Simpson, H.S. (85) 193
Boyer, H., De Gennes, J.L., Truffert, J., Chatellier, G., Dairou, F. and Bruckert, E.
Lp(a) levels in different types of dyslipidemia in the French population (85) 61
Broadhurst, P., Kelleher, C., Hughes, L., Imeson, J.D. and Raftery, E.B.
Fibrinogen, factor VII clotting activity and coronary artery disease severity (85) 169
Brown, W.V., see Hunninghake, D.B. (85) 81
Bruckert, E., see Boyer, H. (85) 61
Burger, K., see Hauner, H. (85) 203

Chamberlain, J.C., see Thorn, J.A. (85) 55
Chan, L., see Thorn, J.A. (85) 55
Chatellier, G., see Boyer, H. (85) 61
Chenchik, A.A., see Babaev, V.R. (85) 239
Chien, S., see Lin, S.-J. (85) 229

Dabach, Y., see Harats, D. (85) 47
Dairou, F., see Boyer, H. (85) 61
Daniel Lamazière, J.M., see Desmoulière, A. (85) 25
Davenport, A.P., see Weissberg, P.L. (85) 257
De Gennes, J.L., see Boyer, H. (85) 61
De Haan, L.H.J., see Zwijsen, R.M.L. (85) 71
Dergunov, A.D., see Babaev, V.R. (85) 239
Desmoulière, A., Daniel Lamazière, J.M. and Larrue, J.
Phenotypic expression of surface antigens of rabbit aortic smooth muscle cells in culture. Monoclonal antibody, 2P1A2, characteristic of smooth muscle cells present in atherosclerotic plaque, is not correlated with cell proliferation (85) 25
Dobs, A.S., see Hunninghake, D.B. (85) 81
Ducimetiere, P., see Raison, J. (85) 185
Durrington, P.N., see MBewu, A.D. (85) 1

Egloff, M., see Raison, J. (85) 185

Filitti, V., see Giral, P. (85) 151
Franzblau, C., see Kaufmann, J. (85) 113
Franzen, J., see Koren, E. (38) 175
Fugate, R.D., see Koren, E. (38) 175

Galton, D.J., see Thorn, J.A. (85) 55
Garcia, R.C., see Nakandakare, E. (85) 211
Giral, P., Filitti, V., Levenson, J., Pithois-Merli, I., Plainfosse, M.-C., Mainardi, C., Gold, A., Simon, A. and PCV-Metra Group,
Relation of risk factors for cardiovascular disease to early atherosclerosis detected by ultrasonography in middle-aged normotensive hypercholesterolemic men (85) 151
Gold, A., see Giral, P. (85) 151
Goldberg, A.C., see Hunninghake, D.B. (85) 81; (85) 219
Guy-Grand, B., see Raison, J. (85) 185

Harats, D., Ben-Naim, M., Dabach, Y., Hollander, G., Havivi, E., Stein, O. and Stein, Y.
Effect of vitamin C and E supplementation on susceptibility of plasma lipoproteins to peroxidation induced by acute smoking (85) 47
Hauner, H., Stangl, K., Schmatz, C., Burger, K., Blömer, H. and Pfeiffer, E.-F.
Body fat distribution in men with angiographically confirmed coronary artery disease (85) 203
Havivi, E., see Harats, D. (85) 47
Hayashi, T., see Tanimura, N. (85) 161
Heistad, D.D., see Armstrong, M.L. (85) 15
Hesketh, T.R., see Weissberg, P.L. (85) 257
Hollander, G., see Harats, D. (85) 47
Hughes, L., see Broadhurst, P. (85) 169

Hunninghake, D.B., Knopp, R.H., Schonfeld, G., Goldberg, A.C., Brown, W.V., Schaefer, E.J., Margolis S., Dobs, A.S., Mellies, M.J., Insull, Jr., W. and Stein, E.A.
Efficacy and safety of pravastatin in patients with primary hypercholesterolemia. I. A dose-response study (85) 81
Hunninghake, D.B., Mellies, M.J., Goldberg, A.C., Kuo, P.T., Kostis, J.B., Schrott, H.G., Insull Jr., W. and Pan, H.Y.
Efficacy and safety of pravastatin in patients with primary hypercholesterolemia. II. Once-daily versus twice-daily dosing (85) 219
Hurst, P.G., see Shi, F. (85) 127

Imeson, J.D., see Broadhurst, P. (85) 169
Insull, Jr., W., see Hunninghake, D.B. (85) 81; (85) 219

Jan, K.-m., see Lin, S.-J. (85) 229
Jay, R.H., Rampling, M.W. and Betteridge, D.J.
Abnormalities of blood rheology in familial hypercholesterolaemia: effects of treatment (85) 249
Jorgensen, R.W., see Kaufmann, J. (85) 113

Kaufmann, J., Jorgensen, R.W., Martin, B.M. and Franzblau, C.
Monocyte activation by smooth muscle cell-derived matrices (85) 113
Kelleher, C., see Broadhurst, P. (85) 169
Kisanuki, A., see Tanimura, N. (85) 161
Knopp, R.H., see Hunninghake, D.B. (85) 81
Koeman, J.H., see Zwijsen, R.M.L. (85) 71
Koren, E., Franzen, J., Fugate, R.D. and Alaupovic, P.
Analysis of cholesterol ester accumulation in macrophages by the use of digital imaging fluorescence microscopy (38) 175
Kostis, J.B., see Hunninghake, D.B. (85) 219
Kuo, P.T., see Hunninghake, D.B. (85) 219

Larrue, J., see Desmoulière, A. (85) 25
Levenson, J., see Giral, P. (85) 151
Lin, S.-J., Jan, K.-m. and Chien, S.
Temporal and spatial changes in macromolecular uptake in rat thoracic aorta and relation to [^{3}H]thymidine uptake (85) 229
Lorimer, A.R., see Simpson, H.S. (85) 193

Maclean, J., see Simpson, H.S. (85) 193
Mainardi, C., see Giral, P. (85) 151
Margolis, S., see Hunninghake, D.B. (85) 81
Martin, B.M., see Kaufmann, J. (85) 113
MBewu, A.D. and Durrington, P.N.
Lipoprotein (a): structure, properties and possible involvement in thrombogenesis and atherogenesis (85) 1
McNamara, D.J., see Shi, F. (85) 127
Mellies, M.J., see Hunninghake, D.B. (85) 81; (85) 219
Metcalfe, J.C., see Weissberg, P.L. (85) 257

Nakandakare, E., Garcia, R.C., Rocha, J.C., Sperotto, G., Oliveira, H.C.F. and Quintão, E.C.R.
Effects of simvastatin, bezafibrate and gemfibrozil on the quantity and composition of plasma lipoproteins (85) 211

Oka, K., see Thorn, J.A. (85) 55
Olivecrona, T., see Simpson, H.S. (85) 193
Oliveira, H.C.F., see Nakandakare, E. (85) 211
Oosting, J.S., see Zwijsen, R.M.L. (85) 71

Packard, C.J., see Simpson, H.S. (85) 193
Pan, H.Y., see Hunninghake, D.B. (85) 219
PCV Metra Group, , see Giral, P. (85) 151
Pekelharing, H.L.M., see Zwijsen, R.M.L. (85) 71
Pfeiffer, E.-F., see Hauner, H. (85) 203
Pithois-Merli, I., see Giral, P. (85) 151
Plainfosse, M.-C., see Giral, P. (85) 151
Pringle, S., see Simpson, H.S. (85) 193

Quintão, E.C.R., see Nakandakare, E. (85) 211

Raftery, E.B., see Broadhurst, P. (85) 169
Raison, J., Bonithon-Kopp, C., Egloff, M., Ducimetiere, P. and Guy-Grand, B.
Hormonal influences on the relationships between body fatness, body fat distribution, lipids, lipoproteins, glucose and blood pressure in French working women (85) 185
Rampling, M.W., see Jay, R.H. (85) 249
Rocha, J.C., see Nakandakare, E. (85) 211

Schaefer, E.J., see Hunninghake, D.B. (85) 81
Schmatz, C., see Hauner, H. (85) 203
Schonfeld, G., see Hunninghake, D.B. (85) 81
Schrott, H.G., see Hunninghake, D.B. (85) 219
Shankar, R. and Bond, M.G.
Correlation of noninvasive arterial compliance with anatomic pathology of atherosclerotic nonhuman primates (85) 37
Shepherd, J., see Simpson, H.S. (85) 193
Shi, F., Hurst, P.G. and McNamara, D.J.
Increased degradation of low density lipoproteins by mononuclear leukocytes associated with coronary artery disease (85) 127
Simon, A., see Giral, P. (85) 151
Simpson, H.S., Williamson, C.M., Olivecrona, T., Pringle, S., Maclean, J., Lorimer, A.R., Bonnefous, F., Bogaievsky, Y., Packard, C.J. and Shepherd, J.
Postprandial lipemia, fenofibrate and coronary artery disease (85) 193
Smirnov, V.N., see Babaev, V.R. (85) 239
Sorg, C., see Babaev, V.R. (85) 239
Sperotto, G., see Nakandakare, E. (85) 211
Stangl, K., see Hauner, H. (85) 203
Stein, E.A., see Hunninghake, D.B. (85) 81
Stein, O., see Harats, D. (85) 47
Stein, Y., see Harats, D. (85) 47
Stocks, J., see Thorn, J.A. (85) 55
Sumiyoshi, A., see Tanimura, N. (85) 161

Tan, M.H., see Barry, L.E. (85) 139
Tanimura, N., Asada, Y., Hayashi, T., Kisanuki, A. and Sumiyoshi, A.
Aortic endothelial cell damage induced by β-VLDL and macrophages in vitro (85) 161

Tararak, E.M., see Babaev, V.R. (85) 239
Thorn, J.A., Chamberlain, J.C., Alcolado, J.C., Oka, K., Chan, L., Stocks, J. and Galton, D.J.
Lipoprotein and hepatic lipase gene variants in coronary atherosclerosis (85) 55
Trakht, I.N., see Babaev, V.R. (85) 239
Truffert, J., see Boyer, H. (85) 61

Weissberg, P.L., Witchell, C., Davenport, A.P., Hesketh, T.R. and Metcalfe, J.C.
The endothelin peptides ET-1, ET-2, ET-3 and sarafotoxin S6b are co-mitogenic with platelet-derived growth factor for vascular smooth muscle cells (85) 257
Williamson, C.M., see Simpson, H.S. (85) 193
Witchell, C., see Weissberg, P.L. (85) 257

Yanushevskaya, E.V., see Babaev, V.R. (85) 239

Zwijsen, R.M.L., De Haan, L.H.J., Oosting, J.S., Pekelharing, H.L.M. and Koeman, J.H.
Inhibition of intercellular communication in smooth muscle cells of humans and rats by low density lipoprotein, cigarette smoke condensate and TPA (85) 71

Atherosclerosis, 85 (1991) 269–270
Elsevier Scientific Publishers Ireland, Ltd.

Subject Index (Vol. 85)

Angiography, (85) 203
Animal models, (85) 15
Antioxidants, (85) 161
Aortic endothelial cell injury, (85) 161
Aortic smooth muscle cells, (85) 113
Apo B/E receptors, (85) 127
Apo B localization, (85) 239
Apo E accumulation, (85) 239
Apolipoprotein A-I, (85) 139
Apolipoprotein B, (85) 139
Apolipoprotein E, (85) 139
Arterial plaques, (85) 151
Atherogenesis, (85) 103
Atherosclerosis, (85) 15; (85) 25; (85) 37; (85) 47; (85) 61; (85) 151; (85) 193; (85) 229; (85) 239

Bezafibrate, (85) 211
Blood viscosity, (85) 249
Body fat distribution, (85) 185; (85) 203

Cardiovascular risk factor, (85) 203
Cardiovascular risk factors, (85) 151
Cell turnover, (85) 229
Cholesterol ester, (38) 175
Cholesterol-feeding, (85) 103
Cholestyramine, (85) 249
Chronic uremia, (85) 139
Chylomicron-Remnants, (85) 103
Chylomicrons, (85) 193
Cigarette smoke condensate, (85) 71
Clinical trial, (85) 81; (85) 219
Compliance, (85) 37
Coronary artery disease, (85) 127; (85) 169
Coronary atherosclerosis, (85) 55
Coronary heart disease, (85) 203
Cortisol binding protein, (85) 185

Digital imaging fluorescence microscopy, (38) 175
DNA, (85) 55
Dose-response, (85) 81

Efficacy, (85) 219
Elastin, (85) 113
Endothelial junction, (85) 229
Endothelin, (85) 257
Endothelium, (85) 229
Evans blue–albumin, (85) 229
Extracellular matrix, (85) 113

Factor VII activity, (85) 169
Fat load test, (85) 193
Fibrinogen, (85) 169; (85) 249
Free cholesterol/phospholipid molar ratio, (85) 139

Gemfibrozil, (85) 211

HDL, (85) 71
Hepatic lipase, (85) 55
High density lipoproteins, (85) 139; (85) 193; (85) 211
HMG-CoA reductase inhibitors, (85) 81; (85) 219
Hypercholesterolemia, (85) 151; (85) 249
Hyperlipidemia, (85) 55; (85) 61
Hyperlipoproteinemia, (85) 103

Image analysis, (85) 257
Insulin, (85) 185
Intercellular communication, (85) 71

LDL, (85) 71
LDL modification, (85) 47
LDL peroxidation, (85) 47
Lipoprotein(a), (85) 61
Lipoprotein composition, (85) 211
Lipoprotein lipase, (85) 55; (85) 193
Lipoproteins, (85) 103
Lipoprotein ultracentrifugation, (85) 211
Low density lipoprotein degradation, (85) 127
Low density lipoproteins, (38) 175; (85) 139; (85) 211

Macrophages, (38) 175; (85) 47
Metabolic risk factors, (85) 185
Mitogens, (85) 257
Monoclonal antibodies, (85) 25
Monocyte/macrophage, (85) 161
Monocytes, (85) 113
Mononuclear leukocyte, (85) 127

NZW rabbits, (85) 103

Overall adiposity, (85) 185

Peripheral arteries, (85) 37
Permeability, (85) 229
Phenotypic modulation, (85) 25
Plasma lipoproteins, (85) 127
Plasma viscosity, (85) 249
Platelet-derived growth factor, (85) 257
Plethysmography, (85) 37

Polymorphism, (85) 55
Post-heparin lipases, (85) 193
Pravastatin, (85) 81; (85) 219; (85) 249
Primary hypercholesterolemia, (85) 219

Red cell aggregation, (85) 249
Red cell deformability, (85) 249
Retinyl palmitate, (85) 103
Reverse cholesterol transport, (85) 239

Safety, (85) 81
Sex hormone binding globulin, (85) 185
Simvastatin, (85) 211
Smoking, (85) 47
Smooth muscle cells, (85) 25; (85) 47

Thiobarbituric acid reactive substances, (85) 47
[^{3}H]Thymidine, (85) 229
Transport, (85) 229
Treatment regimen, (85) 219

Ultrasonography, (85) 151

Validation, (85) 37
Vascular smooth muscle cells, (85) 257
Very low density lipoproteins, (85) 139
Vitamin A, (85) 103
Vitamin C, (85) 47
Vitamin E, (85) 47
β-VLDL, (85) 161

WHHL rabbits, (85) 103